ABSTRACT
Objective To explore the value of extracellular signal-regulated kinase (ERK)-1/2 and p-ERK-1/2 expression in predicting the efficacy of neoadjuvant chemotherapy in cervical squamous cell carcinoma.Methods Fifty-seven patients with cervical squamous cell carcinoma who received neoadjuvant chemotherapy from May 2016 to May 2018 in Bazhong Central Hospital of Sichuan Province were selected.The incidence of adverse reactions during treatment was analyzed.The expression of ERK 1/2 and p-ERK 1/2 in cervical squamous cell carcinoma tissues before and after treatment was compared,and the expression levels of ERK 1/2 and p-ERK 1/2 and the effectiveness of neoadjuvant chemotherapy were analyzed.Results After treatment,the effective rate was 68.42％ (39/57),and the incidence of adverse reactions was 24.56％ (14/57).Before treatment,the positive rate of ERK1/2 was 87.72％ (50/57),after treatment,the positive rate of ERK 1/2 was 31.58％ (18/57),and there were statistical differences (P＜ 0.01).Before treatment,the positive rate of p-ERK 1/2 was 75.44％ (43/57),after treatment,the positive rate of p-ERK 1/2 was 19.30％ (11/57),and there was statistical difference (P ＜ 0.01).The effective rate after treatment in pre-treatment ERK 1/2 positive group was significantly lower than that in pre-treatment ERK 1/2 negative group:53.12％ (17/32) vs.88.00％ (22/25),and there was statistical difference (P ＜ 0.05).The effective rate after treatment in pre-treatment p-ERK 1/2 positive group was significantly lower than that in pre-treatment p-ERK 1/2 negative group:60.47％ (26/43) vs.13/14,and there was statistical difference (P ＜ 0.05).Conclusions ERK 1/2 and p-ERK 1/2 in cervical squamous cell carcinoma can predict the efficacy of neoadjuvant chemotherapy.
ABSTRACT
Objective@#To explore the value of extracellular signal-regulated kinase (ERK)-1/2 and p-ERK-1/2 expression in predicting the efficacy of neoadjuvant chemotherapy in cervical squamous cell carcinoma.@*Methods@#Fifty-seven patients with cervical squamous cell carcinoma who received neoadjuvant chemotherapy from May 2016 to May 2018 in Bazhong Central Hospital of Sichuan Province were selected. The incidence of adverse reactions during treatment was analyzed. The expression of ERK 1/2 and p-ERK 1/2 in cervical squamous cell carcinoma tissues before and after treatment was compared, and the expression levels of ERK 1/2 and p-ERK 1/2 and the effectiveness of neoadjuvant chemotherapy were analyzed.@*Results@#After treatment, the effective rate was 68.42% (39/57), and the incidence of adverse reactions was 24.56% (14/57). Before treatment, the positive rate of ERK1/2 was 87.72% (50/57), after treatment, the positive rate of ERK 1/2 was 31.58% (18/57), and there were statistical differences (P<0.01). Before treatment, the positive rate of p-ERK 1/2 was 75.44% (43/57), after treatment, the positive rate of p-ERK 1/2 was 19.30% (11/57), and there was statistical difference (P<0.01). The effective rate after treatment in pre-treatment ERK 1/2 positive group was significantly lower than that in pre-treatment ERK 1/2 negative group: 53.12% (17/32) vs. 88.00% (22/25), and there was statistical difference (P<0.05). The effective rate after treatment in pre-treatment p-ERK 1/2 positive group was significantly lower than that in pre-treatment p-ERK 1/2 negative group: 60.47% (26/43) vs. 13/14, and there was statistical difference (P<0.05).@*Conclusions@#ERK 1/2 and p-ERK 1/2 in cervical squamous cell carcinoma can predict the efficacy of neoadjuvant chemotherapy.